Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress

Biotechnology Reports Fourth Quarter and Full Year 2018 Results and Recent Corporate Progress

Execution Positions the Company for Expedited Progress in 2019

Aviv, Israel March 18, 2019 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production

technology, today announced operating and financial results for the fourth quarter and full year ended December 31, 2018, as well

as recent corporate progress.

made progress in 2018 as we overcame the short-term setback of patient recruitment in our trial in Israel and moved closer to

the initiation of our U.S. clinical efforts," commented Dr. Shai Yarkoni, Chief Executive Officer. "We continue to

validate our innovative science, and the U.S. Food and Drug Administration's (FDA) recent decision to hire at least 50 clinical

assesors to focus on cell and gene therapy companies is precisely why we believe Cellect will be a major beneficiary in the growth

of this sector - companies and academics need to source stem cells from a reliable and cost effective supplier to develop

their therapies over the next decade and we are positioning Cellect's technology to enable that. Operationally, we recently

strengthened our balance sheet through an underwritten public offering, securing interest from sophisticated healthcare investors

and participation from senior executives from Cellect, which reflects our continued optimism and outlook for 2019. We look forward

to providing an update on our progress in the coming months through a business update conference call."

Operating and Financial Highlights:

Near-Term Milestones:

Results in Israel Continue to Validate the Company's Innovation

Development Initiatives to Drive Commercialization Efforts

Collaboration Agreements

and Enhancing the Company's IP Portfolio

Quarter and Full Year 2018 Financial Results:

the convenience of the reader, the amounts have been translated from NIS into U.S. dollars, at the representative rate of exchange

on December 31, 2018 (U.S. $1 = NIS 3.748).

Cellect Biotechnology Ltd.

Biotechnology (NASDAQ: APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that

aims to improve a variety of stem cell-based therapies.

Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly

isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications

in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations of

these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example,

forward-looking statements are used in this press release when we discuss Cellect's intent regarding the future potential of Cellect's

technology. These forward-looking statements and their implications are based on the current expectations of the management of

the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially

from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research

and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred

to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could

cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses

and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or

at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital

needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical

trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community;

difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks

resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate

collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its

ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies

and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability

to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement

in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update

or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may

be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company

is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal

year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website,

www.sec.gov, and in the Company's periodic filings with the SEC.

Leibovitz, Chief Financial Officer

Polyviou / Todd Kehrli

/ tkehrli@evcgroup.com

Statement of Operation